OCA
Octagon Capital Advisors Portfolio holdings
AUM
$641M
1-Year Est. Return
327.85%
1 Year Est. Return
+327.85%
AUM
$456M
AUM Growth
-$52.5M
(-10%)
Holding
36
Top Buys
| 1 | +$12.7M | |
| 2 | +$11.6M | |
| 3 | +$11.3M | |
| 4 |
DBVT
DBV Technologies
DBVT
|
+$9.31M |
| 5 |
Taysha Gene Therapies
TSHA
|
+$4.37M |
Top Sells
| 1 | +$53M | |
| 2 | +$20.6M | |
| 3 | +$11.1M | |
| 4 |
Scholar Rock
SRRK
|
+$10.6M |
| 5 |
Verastem
VSTM
|
+$10.4M |
Sector Composition
| 1 | Healthcare | 99.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Dianthus Therapeutics
DNTH
$1.75B
| $43.6M | 9.57% |
2,341,667
|
|
||
2
ArriVent BioPharma
AVBP
$854M
| $42.4M | 9.3% |
1,946,054
-113,333
|
|
||
|
VRNA
3
DELISTED
Verona Pharma
VRNA
| $31.9M | 7% |
337,000
+119,736
|
|
||
|
4
Taysha Gene Therapies
TSHA
$1.13B
| $29.1M | 6.38% |
12,592,500
+1,892,500
|
|
||
5
ARS Pharmaceuticals
SPRY
$812M
| $23.6M | 5.17% |
1,350,000
+725,000
|
|
||
6
Gossamer Bio
GOSS
$627M
| $22.6M | 4.95% |
18,350,000
|
|
||
7
Ocular Therapeutix
OCUL
$2.41B
| $22.5M | 4.94% |
2,425,000
|
|
||
8
Merus
MRUS
$7.28B
| $20.5M | 4.49% |
389,000
+81,000
|
|
||
9
Trevi Therapeutics
TRVI
$1.38B
| $20.1M | 4.41% |
3,672,000
+350,000
|
|
||
10
Cogent Biosciences
COGT
$5.15B
| $19.8M | 4.35% |
2,763,000
|
|
||
|
ATYR
11
aTyr Pharma
ATYR
$73.8M
| $19.4M | 4.25% |
3,820,000
+268,000
|
|
||
12
Apellis Pharmaceuticals
APLS
$2.57B
| $15.6M | 3.43% |
903,500
-1,190,500
|
|
||
13
Nuvation Bio
NUVB
$1.67B
| $15M | 3.29% |
7,691,334
-208,666
|
|
||
|
TRML
14
DELISTED
Tourmaline Bio
TRML
| $14.5M | 3.18% |
905,000
|
|
||
15
KalVista Pharmaceuticals
KALV
$688M
| $14.4M | 3.16% |
1,273,333
-96,667
|
|
||
16
MindMed
MNMD
$1.1B
| $13.8M | 3.03% |
2,130,000
-888,000
|
|
||
|
CNTA
17
Centessa Pharmaceuticals
CNTA
$3.71B
| $13.5M | 2.97% |
1,030,000
-395,000
|
|
||
18
Pharvaris
PHVS
$1.53B
| $11.8M | 2.6% |
672,595
-97,220
|
|
||
19
Kymera Therapeutics
KYMR
$4.67B
| $11.6M | 2.55% |
+266,000
|
|
||
|
ABVX
20
Abivax
ABVX
$8.59B
| $9.69M | 2.13% |
1,267,000
+37,000
|
|
||
|
DBVT
21
DBV Technologies
DBVT
$476M
| $9.31M | 2.04% |
+1,018,021
|
|
||
22
Corbus Pharmaceuticals
CRBP
$194M
| $7.69M | 1.69% |
1,115,000
|
|
||
23
MoonLake Immunotherapeutics
MLTX
$905M
| $6.99M | 1.53% |
148,000
-148,000
|
|
||
24
Unicycive Therapeutics
UNCY
$122M
| $4.77M | 1.05% |
1,000,000
|
|
||
25
Neurogene
NGNE
$325M
| $4.53M | 0.99% |
303,000
|
|